Horizon Therapeutics plc announced that the FDA has accepted Horizon's New Drug Application (NDA) for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral...
Horizon Therapeutics plc announced that the FDA has approved Procysbi (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis.